| 武晓玲,姜义卿,郑 群,扈晓霞,袁兰所.替罗非班联合尼可地尔对急诊PCI患者心功能和短期预后的影响[J].现代生物医学进展英文版,2018,(9):1750-1753. |
| 替罗非班联合尼可地尔对急诊PCI患者心功能和短期预后的影响 |
| Effect of Nicorandil Combined with Tirofiban on Cardiac Function and Short-Term Prognosis of Patients with Acute Myocardial Infarction undergoing Primary PCI |
| Received:July 31, 2017 Revised:September 01, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.09.032 |
| 中文关键词: 尼可地尔 替罗非班 急诊PCI 心功能 预后 |
| 英文关键词: Nicorandil Tirofiban Primary PCI Heart Failure Short-term prognosis |
| 基金项目:河北省科技进步基金项目（20161237） |
|
| Hits: 601 |
| Download times: 330 |
| 中文摘要: |
| 摘要 目的：探讨急诊PCI患者在联合使用 替罗非班和尼可地尔后对心功能和短期预后的影响。方法：入选98例接受急诊PCI的AMI患者随机分为对照组（n=49）和联合治疗组（n=49）。对照组单纯给予替罗非班治疗，联合治疗组在对照组基础上给予尼可地尔5 mg tid口服治疗。观察记录两组患者治疗8周前后LVEF、NT-proBNP水平，并随访MACE事件发生情况。结果：两组患者在治疗前LVEF及NT-proBNP水平比较没有统计学差异（P>0.05）。在治疗8周后联合治疗组和对照组LVEF及NT-proBNP水平均较治疗前水平明显改善（P<0.05）。治疗8周后联合治疗组患者LVEF及NT-proBNP水平明显优于对照组患者（P<0.05）。经过8周的治疗，联合治疗组再次发生心绞痛事件（6.12% VS 24.49%，P=0.025）、恶性心律失常（2.04% VS 16.33%，P=0.036）和心力衰竭事件（2.04% VS 18.37%，P=0.020）明显低于对照组。结论：替罗非班联合尼可地尔可进一步改善急诊PCI患者心功能及短期预后，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of nicorandil combined with tirofiban on cardiac function and short-term progno- sis of patients with acute myocardial infarction (AMI) undergoing primary PCI (pPCI). Methods: A total of 98 AMI patients with pPCI were enrolled and divided into combination therapy group (receiving nicorandil and tirofiban, n=49) and control group (receiving tirofiban only, n=49). Left ventricular ejection fraction (LVEF), NT-proBNP and short-term major adverse cardiovascular events were recorded and analyzed after 8 weeks' therapy. Results: There were no statistical significance achieved of LVEF and NT-proBNP before treatment (P>0.05). Compared to that before enrolled, LVEF and NT-proBNP were improved in both groups after 8 weeks' therapy (P<0.05). LVEF and NT-proBNP were improved in combination therapy group, compared to control group after 8 weeks' therapy (P<0.05). Rates of angina pectoris (6.12% VS 24.49%, P=0.025), malignant arrhythmia (2.04% VS 16.33%, P=0.036) and heart failure (2.04% VS 18.37%, P=0.020) of combination therapy group were lower compared to control groupduring 8 weeks' therapy. Conclusion: Nicorandil combined with tirofiban has more pronounced effect for improving cardiac function and short term prognosis of pPCI patients, worth clinical promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
